Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
1. Opus Genetics dosed the first patient in Phase 3 trial LYNX-3. 2. LYNX-3 tests Phentolamine for night vision impairment post-refractive surgery. 3. FDA granted Fast Track designation to Phentolamine for treating visual disturbances. 4. Positive results from the previous trial LYNX-2 bolster confidence in LYNX-3. 5. Opportunity exists to address a critical need for millions of patients.